[go: up one dir, main page]

KR970703132A - 듀오카르마이신 유도체의 안정화 방법(method for stabilizing duocarmycin derivatives) - Google Patents

듀오카르마이신 유도체의 안정화 방법(method for stabilizing duocarmycin derivatives) Download PDF

Info

Publication number
KR970703132A
KR970703132A KR1019960706549A KR19960706549A KR970703132A KR 970703132 A KR970703132 A KR 970703132A KR 1019960706549 A KR1019960706549 A KR 1019960706549A KR 19960706549 A KR19960706549 A KR 19960706549A KR 970703132 A KR970703132 A KR 970703132A
Authority
KR
South Korea
Prior art keywords
group
duocarmycin
surfactants
polyhydric alcohols
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019960706549A
Other languages
English (en)
Inventor
데이비드 알렉산더 타인쉬
트레버 레슬리 일로트
도로시 질 스넬
리 퐁 람
게르하르트 게르겔리
이름가르트 게르겔리
토마스 게르겔리
마사시 나까꾸라
유지 우에노
에이지 하야까와
도꾸유끼 구로다
Original Assignee
게르하르트 게르겔리
그라함 브레레톤
글락소 웰컴 오스트레일리아 리미티드
히라따 다다시
교오와 학꼬 고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게르하르트 게르겔리, 그라함 브레레톤, 글락소 웰컴 오스트레일리아 리미티드, 히라따 다다시, 교오와 학꼬 고오교 가부시끼가이샤 filed Critical 게르하르트 게르겔리
Publication of KR970703132A publication Critical patent/KR970703132A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

하기 화학식(1)의 안정화된 듀오카르마이신 유도체:
(여기서, R은 저급 알킬기, 알릴기 또는 벤질기를 나타내고, X는 염소 원자 또는 브롬 원자를 나타낸다)를 당류, 전해질, 수용성 중합체, 다가 알콜 및 계면활성제로 구성된 군에서 선택된 한 개 이상의 화합물을 듀오카르마이신 유도체를 함유하는 용액에 첨가함으로서 제조한다. 또한, 안정화된 듀오카르마이신 유도세를 함유하는 동결 건조된 약제학적 제제를 제공한다.

Description

듀오카르마이신 유도체의 안정화 방법(METHOD FOR STABILIZING DUOCARMYCIN DERIVATIVES)
[도면의 간단한 설명]
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 당류, 전해질, 수용성 중합체, 다가 알콜 및 계면활성제로 이루어진 군에서 선택된 한 개 이상의 화합물을 하기 듀오카르마이신 유도체를 함유하는 용액에 첨가하는 것을 특징으로 하는, 하기 화학식(1)의 듀오카르마이신 유도체의 안정화 방법:
    (여기서, R은 저급 알킬기, 알릴기 또는 벤질기를 나타내고, X는 염소 원자 또는 브롬 원자를 나타낸다).
  2. 제1항에 있어서, 상기 듀오카르마이신 유도체를 및 당류를 함유하는 용액을 동결 건조시키는 안정화 방법.
  3. 제2항에 있어서, 용액이 전해질, 수용성 중합체, 다가 알콜 및 계면활성제로 이루어진 군에서 선택된 한 개 이상의 추가 화합물을 함유하는 안정화 방법.
  4. 듀오카르마이신 유도체 및 당류, 전해질, 수용성 중합체, 다가 알콜 및 계면활성제로 이루어진 군에서 선택된 한개 이상의 화합물을 함유하는 산성 용액을 동결 건조시킴으로써 수득되는 화학식(1)의 듀오카르마이신 유도체를 함유하는 약제학적 조성물:
  5. 제4항에 있어서, 용액이 동결 건조 이전에 듀오카르마이신 유도체 및 당류를 함유하는 것을 특징으로 하는 동결 건조된 약제학적 조성물.
  6. 제5항에 있어서, 용액이 또한 동결 건조 이전에 진해질, 수용성 중합체, 다가 알콜 및 계면활성제로 이루어진 군에서 선택된 한개 이상의 화합물을 함유하는 것을 특징으로 하는 동결 건조된 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960706549A 1994-05-20 1995-05-19 듀오카르마이신 유도체의 안정화 방법(method for stabilizing duocarmycin derivatives) Withdrawn KR970703132A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP94-106415 1994-05-20
GB9410222.5 1994-05-21
GB9410222A GB9410222D0 (en) 1994-05-21 1994-05-21 Medicaments
CH1890/94.0 1994-06-15

Publications (1)

Publication Number Publication Date
KR970703132A true KR970703132A (ko) 1997-07-03

Family

ID=10755515

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019960706549A Withdrawn KR970703132A (ko) 1994-05-20 1995-05-19 듀오카르마이신 유도체의 안정화 방법(method for stabilizing duocarmycin derivatives)
KR1019960706578A Expired - Lifetime KR100361413B1 (ko) 1994-05-21 1995-05-19 플루티카손 프로피오네이트 제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019960706578A Expired - Lifetime KR100361413B1 (ko) 1994-05-21 1995-05-19 플루티카손 프로피오네이트 제제

Country Status (28)

Country Link
US (1) US5993781A (ko)
EP (1) EP0760649B1 (ko)
JP (1) JPH10500420A (ko)
KR (2) KR970703132A (ko)
CN (1) CN1098680C (ko)
AT (1) ATE207734T1 (ko)
AU (1) AU710821B2 (ko)
BR (1) BR9507746A (ko)
CA (1) CA2190763A1 (ko)
CY (1) CY2294B1 (ko)
CZ (1) CZ285966B6 (ko)
DE (1) DE69523587T2 (ko)
DK (1) DK0760649T3 (ko)
ES (1) ES2164767T3 (ko)
FI (1) FI118512B (ko)
GB (1) GB9410222D0 (ko)
HU (1) HU223316B1 (ko)
IL (1) IL113794A (ko)
MX (1) MX9605650A (ko)
NO (1) NO313785B1 (ko)
NZ (1) NZ287425A (ko)
PL (1) PL180318B1 (ko)
PT (1) PT760649E (ko)
RU (1) RU2161485C2 (ko)
SI (1) SI0760649T1 (ko)
TW (1) TW438604B (ko)
WO (1) WO1995031964A1 (ko)
ZA (1) ZA954101B (ko)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4484247B2 (ja) * 1995-02-24 2010-06-16 エラン ファーマ インターナショナル，リミティド ナノ粒子分散体を含有するエアロゾル
GB9610341D0 (en) * 1996-05-17 1996-07-24 Andaris Ltd Formulation for inhalation
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
EP1280520B2 (en) 2000-05-10 2018-03-21 Novartis AG Phospholipid-based powders for drug delivery
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
PT2348032E (pt) 2000-08-05 2015-10-14 Glaxo Group Ltd Éster s-fluorometílico do ácido 6.alfa.,9.alfa.-difluoro- 17.alfa.-'(2-furanilcarboxil)oxi]-11.beta.-hidroxi-16.alfa.- metil-3-oxo-androsta-1,4-dieno-17-carbotióico como um agente anti-inflamatório
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
CA2445839A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
ATE508735T1 (de) 2001-12-19 2011-05-15 Novartis Ag Pulmonale verabreichung von aminoglykosiden
AU2003210517A1 (en) 2002-02-04 2003-09-02 Elan Pharma International, Ltd. Drug nanoparticles with lysozyme surface stabiliser
WO2003070285A1 (en) 2002-02-19 2003-08-28 Resolution Chemicals Limited Solvent-based sterilisation of pharmaceuticals
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
WO2004032980A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
EP1454636A1 (en) * 2003-03-04 2004-09-08 Dompé S.P.A. Sterilization of glucocorticoid drug particles for pulmonary delivery
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
CA2523035C (en) * 2003-05-22 2011-04-26 Elan Pharma International Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
DE602005026225D1 (de) 2004-03-12 2011-03-24 Cipla Ltd Sterilisationsprozess für Steroide
GB0410995D0 (en) * 2004-05-17 2004-06-23 Norton Healthcare Ltd Heat sterilization of glucocorticosteroids
GB0425266D0 (en) 2004-11-16 2004-12-15 Norton Healthcare Ltd Pharmaceutical manufacturing process
GB0427568D0 (en) * 2004-12-16 2005-01-19 Resolution Chemicals Ltd Particle-size reduction apparatus, and the use thereof
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CN102166219B (zh) * 2010-05-25 2013-04-17 杭州天龙药业有限公司 一种鼻腔给药制剂及其应用
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
IN2014DN09326A (ko) 2012-05-08 2015-07-10 Aciex Therapeutics Inc
CN103505412A (zh) * 2012-06-26 2014-01-15 上海臣邦医药科技有限公司 一种吸入用丙酸氟替卡松混悬液的制备方法
US20150165037A1 (en) 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol
WO2014007781A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
DE102012111077A1 (de) * 2012-11-16 2014-05-22 Justus-Liebig-Universität Giessen Optimierung von Vernebelungseigenschaften einer Lösung oder eines Kolloids
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
CA2959943C (en) 2014-09-15 2022-08-16 Verona Pharma Plc Liquid inhalation formulation comprising rpl554
CN112997256A (zh) 2018-06-14 2021-06-18 阿斯利康(英国)有限公司 使用皮质类固醇医药组合物治疗和预防哮喘症状的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB2235627B (en) * 1989-09-08 1993-09-01 Glaxo Group Ltd Inhalation medicaments for treating respiratory disorders
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
CA2421976C (en) * 1991-12-12 2004-04-20 Glaxo Group Limited Medicaments
ATE128350T1 (de) * 1991-12-12 1995-10-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung.
CZ288032B6 (cs) * 1991-12-18 2001-04-11 Aktiebolaget Astra Farmaceutický prostředek pro podání inhalací
US5301664A (en) * 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
GB9419536D0 (en) * 1994-09-28 1994-11-16 Glaxo Inc Medicaments
RU2135183C1 (ru) * 1996-02-29 1999-08-27 Государственный научно-клинический центр охраны здоровья шахтеров Способ лечения гормонозависимой бронхиальной астмы

Also Published As

Publication number Publication date
HK1004192A1 (en) 1998-11-20
CY2294B1 (en) 2003-07-04
ES2164767T3 (es) 2002-03-01
FI118512B (fi) 2007-12-14
SI0760649T1 (en) 2002-04-30
CN1098680C (zh) 2003-01-15
US5993781A (en) 1999-11-30
PT760649E (pt) 2002-04-29
CN1148804A (zh) 1997-04-30
MX9605650A (es) 1998-05-31
IL113794A (en) 2000-10-31
IL113794A0 (en) 1995-08-31
EP0760649A1 (en) 1997-03-12
BR9507746A (pt) 1997-08-19
DE69523587D1 (de) 2001-12-06
DK0760649T3 (da) 2002-01-28
FI964634A0 (fi) 1996-11-20
JPH10500420A (ja) 1998-01-13
WO1995031964A1 (en) 1995-11-30
NO313785B1 (no) 2002-12-02
AU2614595A (en) 1995-12-18
ATE207734T1 (de) 2001-11-15
DE69523587T2 (de) 2002-06-27
PL317225A1 (en) 1997-03-17
EP0760649B1 (en) 2001-10-31
CZ342396A3 (en) 1997-07-16
GB9410222D0 (en) 1994-07-06
HU9603227D0 (en) 1997-01-28
HUT76552A (en) 1997-09-29
TW438604B (en) 2001-06-07
NZ287425A (en) 1998-05-27
AU710821B2 (en) 1999-09-30
FI964634L (fi) 1996-11-20
KR970703130A (ko) 1997-07-03
NO964938L (no) 1996-11-20
PL180318B1 (pl) 2001-01-31
CZ285966B6 (cs) 1999-12-15
KR100361413B1 (ko) 2003-02-19
RU2161485C2 (ru) 2001-01-10
CA2190763A1 (en) 1995-11-30
HU223316B1 (hu) 2004-05-28
ZA954101B (en) 1996-01-29
NO964938D0 (no) 1996-11-20

Similar Documents

Publication Publication Date Title
KR970703132A (ko) 듀오카르마이신 유도체의 안정화 방법(method for stabilizing duocarmycin derivatives)
BR9507640A (pt) Processo para estabilizar derivados de duocarmicida e composição farmacêutica
CA2295599A1 (en) Novel heterocyclic analogs of diphenylethylene compounds
DK1073439T3 (da) Farmaceutisk sammensætning
KR970009800A (ko) 경구 투여용 약제학적 조성물
DE60023465D1 (de) Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
AP1784A (en) Method and composition for improving fuel combustion
KR950703946A (ko) 탁산 유도체를 기재로 한 주사용 조성물(injectable taxane derivative based compositions)
KR850004391A (ko) 비-수성 아이버멕틴 제형
IE811751L (en) Aqueous formulation
CA2419067A1 (en) Injectable composition comprising benzimidazole compound and strong alkali
KR890006644A (ko) 결정성 β-락탐 수화물
FR2548676B1 (fr) Compositions de biopolymeres et leur procede de preparation
EP0821946A3 (de) Stabile Lichtschutzzubereitungen mit einem Gehalt an grenzflächen aktive Glucosederivaten und wasserlöslichen UV-Filtersubstanzen
CA2365265A1 (en) Stable aqueous compositions containing a silicon compound
KR970005016A (ko) 2'-데옥시-2 -메틸리덴시티딘 이수화물 함유 조성물
IE791875L (en) Sodium amoxicillin preparations
CA2358361A1 (en) Stable compositions for parenteral administration and their use
KR890012960A (ko) 결정성 β-락탐 용매화물
RU96124085A (ru) Способ стабилизации производных дуокармицина
KR910004620A (ko) 위궤양 치료제
KR950704335A (ko) 포스폰산 디에스테르 유도체(phosphonic diester derivative)
RU2001105547A (ru) Жидкий состав
RU98116461A (ru) Комплекс 1-(2-гидроксиэтил)-2-метил-5-нитромидазола с поливинилпирролидоном, способ получения, фармацевтическая композиция, обладающая антимикробным действием
SE9002508D0 (sv) Asymmetric synthesis of furo (3,4-c) pyridine derivatives

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19961119

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid